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Expression of the chemokine receptor CXCR4 allows breast cancer cells to migrate towards specific metastatic target sites which
constitutively express CXCL12. In this study, we determined whether this interaction could be disrupted using short-chain length
heparin oligosaccharides. Radioligand competition binding assays were performed using a range of heparin oligosaccharides to
compete with polymeric heparin or heparan sulphate binding to I
125 CXCL12. Heparin dodecasaccharides were found to be the
minimal chain length required to efficiently bind CXCL12 (71% inhibition; Po0.001). These oligosaccharides also significantly inhibited
CXCL12-induced migration of CXCR4-expressing LMD MDA-MB 231 breast cancer cells. In addition, heparin dodecasaccharides
were found to have less anticoagulant activity than either a smaller quantity of polymeric heparin or a similar amount of the low
molecular weight heparin pharmaceutical product, Tinzaparin. When given subcutaneously in a SCID mouse model of human breast
cancer, heparin dodecasaccharides had no effect on the number of lung metastases, but did however inhibit (Po0.05) tumour
growth (lesion area) compared to control groups. In contrast, polymeric heparin significantly inhibited both the number (Po0.001)
and area of metastases, suggesting a differing mechanism for the action of polymeric and heparin-derived oligosaccharides in the
inhibition of tumour growth and metastases.
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Breast cancer is the most common malignancy in women and a
major cause of morbidity and mortality in many parts of the world.
The main cause of these deaths is metastatic spread of the disease
(Dowsland et al, 2003). Breast cancer cells metastasise to specific
anatomical sites, which include the brain, liver, lung and regional
lymph nodes (Woodhouse et al, 1997). It appears that the
metastatic spread of breast cancer cells to specific organs is
dependant on the ability of these organs to express factor(s) that
mediate specific cancer cell extravasation and recruitment from
the blood, across the vascular endothelium and into the sub-
endothelial tissue compartment. This process has clear parallels
with the normal mechanism of leukocyte trafficking which is
driven by chemokines (Muller et al, 2001).
Chemokines are small structurally related chemo-attractant
cytokines that exert their effects locally in a paracrine or autocrine
manner. Chemokines signal through G-protein-coupled receptors
on cells inducing cytoskeletal rearrangement, firm adhesion to
endothelial cells and directional migration (Zlotnik and Yoshie,
2000). These secreted proteins act in a co-ordinated fashion with
cell-surface proteins, including integrins, to direct specific homing
of various subsets of haematopoietic cells to specific anatomical
sites (Moser et al, 2004).
There is increasing evidence that cancer cells express both
chemokines and their receptors allowing both autocrine and
paracrine responses, leading to migration, enhanced proliferation
and cell survival (Azenshtein et al, 2002; Chen et al, 2006; Zlotnik,
2006). Indeed, metastatic breast cancer cells have been shown to
express high levels of the chemokine receptor CXCR4 (Moore,
2001). In addition, organs commonly associated with being sites of
breast cancer metastasis, such as lung, liver, lymph node, brain and
bone, constitutively express the sole ligand for CXCR4, CXCL12
(Muller et al, 2001). Until recently, the interaction between CXCL12
and CXCR4 appeared to be unique and non-promiscuous.
However, it has recently been argued that CXCL12 can interact
with an additional receptor RDC1 (CXCR7), which is not thought to
be involved in migration (Balabanian et al, 2005). Importantly,
when signalling through CXCR4, CXCL12 stimulates intracellular
calcium-flux and chemotaxis in lymphocytes, leukocytes and a
range of cancer cells including breast (Amara et al, 1999; Fernandis
et al, 2004). Although RDC1 is expressed by a number of cancer cell
lines, it does not induce an intracellular calcium-flux or migration
but may promote cell survival and adhesion (Burns et al, 2006).
The presentation of chemokines to their receptors in vivo is
dependent on the glycosaminoglycan (GAG) components of cell
surface or extracellular matrix proteoglycan molecules. Binding
occurs between anionic, sulphated GAG residues and basic amino-
acid domains within the chemokine primary structure (Ali et al,
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s2000). Mutagenesis studies have shown that GAG-binding is
necessary before chemokines can stimulate normal cell migration
in vivo (Ali et al, 2005; Proudfoot, 2006). It has been proposed that
the immobilisation of chemokines by GAGs is required to support
the stable, solid-phase chemokine concentration gradients neces-
sary for leukocyte trafficking in vivo (Kuschert et al, 1999). Binding
of chemokines to cell surface GAGs may also increase their local
concentration (Hoogewerf et al, 1997), resulting in more sensitive
signalling by specific chemokine receptors. Heparan sulphate is a
polysulphated, highly negatively charged GAG synthesised in the
Golgi, and is the predominant GAG present on the apical surface of
vascular endothelial cells (Esko and Lindahl, 2001).
It is now thought that the metastasis of breast cancer cells is
driven by the presentation of CXCL12 by heparan sulphate on the
vascular endothelium and ECM. This induces the activation of
integrins on CXCR4-expressing breast cancer cells which causes
transendothelial migration of the cells followed by growth and
angiogenesis resulting in secondary tumours (Beckmann et al,
1997; Murphy, 2001; Kucia et al, 2004; Luker and Luker, 2006).
In vivo studies have confirmed the importance of CXCL12/CXCR4
interactions in breast cancer metastasis. Muller et al (2001)
employed antibodies against CXCR4 in a model of breast cancer
metastasis over 28 days, which dramatically reduced the incidence
of lung metastases by 67%. A number of studies have investigated
the knock down of CXCR4 using siRNA in breast cancer models.
Liang et al (2005) demonstrated a significant decrease in the
number of metastases in SCID mice inoculated with MDA-MB 231
cells transfected with CXCR4 siRNA compared to controls.
It is already known that the binding of chemokine to soluble
heparan sulphate or heparin can inhibit the activation of
leukocyte-borne chemokine receptors and prevent chemokine-
dependant lymphocyte adhesion and migration (Kuschert et al,
1999; Ali et al, 2000; Sadir et al, 2001; Hecht et al, 2004).
Heparinoids therefore provide a potential approach for inhibiting
breast cancer metastasis, although their anticoagulant activity
might complicate clinical application.
The current study was designed to determine the minimal chain
length of a heparin oligosaccharide that could significantly inhibit
CXCL12-mediated breast cancer metastasis, while abrogating the
potential anticoagulation problems associated with the use of
heparin as an antimetastatic treatment. A series of in vitro
experiments were performed to determine the shortest length of
oligosaccharide capable of competing CXCL12 from a solid-phase
of heparin or heparan sulphate matrix and inhibiting breast cancer
cell migration, while exerting little or no anticoagulant effect. Once
the minimum length oligosaccharide was determined, in vivo
experiments were designed to investigate the antagonistic effects of
these oligosaccharides when compared to polymeric heparin on the
haematological metastasis of CXCR4 expressing breast cancer cells.
A final series of in vitro experiments were performed to define a
candidate mechanism for the antimetastatic effect produced by
heparinoids in vivo. We determined that a dodecasaccharide, an
oligosaccharide composed of 12 monomeric sugar units (dp12) was
the shortest length oligosaccharide able to significantly compete for
CXCL12 binding against heparan sulphate in vitro. Dodecasaccha-
rides exerted less anticoagulation activity than either polymeric
heparin or the low molecular weight heparin Tinzaparin. Heparin
significantly inhibited the formation of lung metastases in vivo.
However, dp12 did not reduce the number of lung metastases, but
did reduce the area of individual lesions.
MATERIALS AND METHODS
Preparation of oligosaccharides
Three 2ml vials of the low molecular weight heparin product
Tinzaparin (Leo Pharmaceuticals, Princes Risborough, UK), were
pooled and applied to two Bio-Gel P10 columns (3 120cm;
Bio-Rad, Hamel Hempstead, UK) linked in series and eluted with
0. 25 M NH4HCO3 at a flow rate of 9mlh
 1. Tinzaparin is produced
through the enzymatic degradation of polymeric heparin using the
enzyme heparinase I (Linhardt and Gunay, 1999). Fractions of 3ml
were collected; their absorbance at 232nm measured and relevant
fractions pooled. After lyophilisation, the samples were dissolved
at a concentration of 100mgml
 1 before precipitation with three
volumes of ice-cold ethanol containing 5% potassium acetate
(Sigma, Poole, UK). The samples were centrifuged, the supernatant
removed and the pellets left to dry overnight at room temperature
before being weighed. This procedure typically yielded around
10mg of oligosaccharide and was repeated as necessary to obtain
sufficient quantities of oligosaccharide material. Fractions pooled
to obtain dp24 and dp26 oligosaccharides are approximations as
no clear peak corresponding to these size pools was directly
detected within the size-exclusion profile of Tinzaparin.
Radioligand binding assays
Scintillant-coated 96-well plates (Flashplate; PerkinElmer, Waltham,
MA, USA) were treated overnight with 200ml of 0.25mgml
 1. Poly-
L-lysine hydrobromide (PLL; Sigma) in PBS. Following washing
with 0.01 M PBS, the wells were incubated with 250ml of heparin
(H3400; Sigma) or heparan sulphate (Sigma) at a concentration of
50mgml
 1 in PBS for 2h at 371C; negative control wells contained
only PBS. The wells were then washed twice in binding buffer (1mM
CaCl2,5 m M MgCl2, 0.5% BSA, 50mM HEPES; pH 7.2). Soluble
competitor was added in a volume of 150ml per well at desired
concentrations followed by the addition of 5nM unlabelled CXCL12
(PeproTech EC LTD, London, UK) with a tracer concentration of
100pM
125I-CXCL12 (PerkinElmer) in a volume of 50ml in binding
buffer. The plates were incubated at room temperature for 3h with
shaking and the solution was removed from each well. After
washing three times with 200ml of binding buffer the bound
radioactivity was measured in a scintillation counter (Microbeta;
LKB Wallac, PerkinElmer, Waltham, MA, USA).
Chemotaxis assays
LMD MDA-MB 231 cells were assayed for their ability to migrate
through an 8mm pore diameter filter membrane (Falcon culture
inserts; Becton Dickinson, Cowley, UK) towards 12.5nM CXCL12.
200000 cells were placed in the upper chamber and the lower
chamber was loaded with medium containing 12.5nM CXCL12 and
varying concentrations of dp12. The assay was incubated for 8h at
371C before removal of excess cells and medium from both
chambers. The upper surface of each filter was gently swabbed
before removal and fixation in methanol at 01C for 1h. The filters
were then stained with 0.1% Mayer’s haematoxylin (Sigma) for
10min, followed by a 10min wash in Scott’s tap water (166mM
MgSO4,2 4 m M NaHCO3). Finally, the filters were sequentially
dehydrated with 50, 75, 90 and 100% ethanol, air-dried and
mounted. Migrant cells on each filter were identified by high-
power microscopy ( 40) and counted in nine randomly selected
fields; the operator was blinded to the treatments.
Anti-coagulation assay
The anti-coagulation effects (anti-Xa activity) of heparin
(2.2mgml
 1), Tinzaparin (3.4mgml
 1; Leo Pharmaceuticals), and
dp12 oligosaccharides (0–34mgml
 1) were examined in plasma.
Whole blood mixed with an appropriate heparinoid was added to
citrated blood collection tubes and immediately analysed. Briefly,
the plasma was centrifuged at 3000g for 20min and transferred to
fresh tubes. The anti-Xa level of each sample was then assessed
using the Biophen heparin 6 kit (Hyphen BioMed, Neuville-sur-
Oise, France) and the COAG-A-MATE MTX II (BioMerieux, Marcy
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sl’Etoile, France) coagulation analyser. Each batch of samples was
analysed in conjunction with Biophen low molecular weight
heparin (LMWH) control plasma and Biophen heparin control
plasma (Hyphen Biomed) as standards.
In vivo metastasis study
All animal experiments were performed in accordance with local
ethical review committee and Home Office Project Licence (PPL
60/3375) approval. All reasonable efforts were made to minimise
the suffering likely to be caused and the number of animals to be
used. All animals were inspected daily by a qualified technician
and weighed twice weekly to ensure thorough assessment of the
health of all animals involved.
CB-17 severe combined immunodeficient (SCID) mice (Charles
River Labs, Wilmington, MA, USA) were injected subcutaneously
with 3.3mgkg
 1day
 1 (600IUkg
 1day
 1) of heparin in PBS every
12h, once a day with dp12 in PBS (4.0mgkg
 1day
 1) or with PBS
alone. Seven mice were treated in each group. Four hours after the
first PBS/heparinoid injection, mice were injected with 2 10
5 LMD
MDA-MB 231 breast carcinoma cells into the tail vein. Lungs were
collected on day 28 and fixed for histopathology. Twenty sections
were cut from each mouse lung at intervals of 50mm in depth.
Lung sections were assessed blindly at  10 magnification
(Leica DMR) and the area of metastasis was calculated using Leica
Q-Win software. Both the number and area of the metastatic
lesions were assessed blindly by two separate investigators (Paul
Mellor and James Harvey).
CXCL12 immunohistochemistry of frozen tissue
Serial sections (5mm thick) of mouse lung were fixed in acetone for
10min at room temperature and then air dried. Following a wash
for 5min in tris-buffered saline (TBS), endogenous peroxidase
activity was blocked by incubating for a further 5min in 0.6% H2O2
in methanol. Sections were then rinsed in distilled water and washed
for a further 5min in TBS; antigen retrieval was not necessary.
Endogenous avidin and biotin were blocked (SP-2001; Vector Labs,
Peterborough, UK). Non-specific binding of the secondary antibody
was prevented by incubation of the sections with 20% rabbit’s
serum in TBS for 1h at 41C. Sections were then incubated overnight
at 41C with primary antibody anti-CXCL12 (Mab310; Sigma) at a
concentration of 1/20 in 20% rabbit’s serum/TBS solution. Two
control sections per tumour were also incubated in every run of
immunohistochemistry; these sections were incubated overnight
with no primary antibody (20% rabbit’s serum/TBS alone).
Following washing in TBS, sections were incubated for 1h at room
temperature with a rabbit-anti-mouse biotinylated secondary anti-
body (1/250; Dako, Ely, UK). After a further wash step in TBS,
sections were incubated for 30min in the dark with a Streptavidin
ABC complex (Vectastain ABC; Vector Labs) at room temperature.
A final wash step was performed before incubation with NiDAB
(SK-4100 substrate kit; Vector Labs) for visualisation.
Light counterstaining with Haematoxylin (Sigma) was per-
formed on all specimens before mounting; this enabled visualisa-
tion of the tissue architecture without masking of the NiDAB
staining. Sections unstained with antibody were dual stained with
Haematoxylin and Eosin (H&E) to demonstrate the tissue
architecture in serial sections. Slides were dehydrated through a
series of alcohol baths (50, 70, 90, 95 and 100% alcohol), cleared in
xylene and mounted using dibutylphthalate xylene. Sections were
compared with controls, where lungs were stained with an isotype
control instead of an anti-CXCL12 primary antibody.
CXCR4 real-time RT-PCR
Total RNA was isolated from murine lung tissue using Trizol (Life
Technologies, Paisley, UK) and cDNA was generated using oligo-dT
primers with the Superscript II RNase reverse transcription system
(Invitrogen, Paisley, UK). Real-time TaqMan PCR was performed
according to Applied Biosystems protocols. All samples were
loaded in triplicate wells and fluorescence emission detected by
the ABI Prism 7000 (Applied Biosystems, Foster City, CA, USA).
Primers and probes for CXCR4 were purchased from Applied
Biosystems. All results were normalised to the expression of
endogenous glyceraldehydes-3-phosphate dehydrogenase mRNA
and expressed as a relative increase or decrease in expression
compared to PBS controls.
Statistical analysis
Data values for radioligand binding, chemotaxis assays and in vivo
metastasis model were expressed as means7s.e.m. Statistical
analysis was performed using an unpaired two-tailed Student’s
t-test or using a one-way analysis of variance when multiple data
sets are being compared; Po0.05 was considered significant.
RESULTS
Determination of shortest-length oligosaccharide of
heparin capable of significantly competing CXCL12 from
heparan sulphate
Radioligand binding assays were performed to determine the
potential of varying concentrations of soluble heparin and heparin
oligosaccharides to compete with polymeric heparin or heparan
sulphate to bind
125I-CXCL12. Initially, polymeric heparin and the
oligosaccharides dp26–dp8 were used at a constant concentration
of 7mgml
 1 (representative molar concentrations: dp26–0.9mM,
dp8–3mM), determined from the IC50 of the dp26 oligosaccharides
(results not shown), to compete CXCL12 from a solid phase of
heparin. Polymeric heparin and the oligosaccharides dp26–dp16
all competed significantly (Po0.001; Figure 1A) with solid-phase
heparin, whereas the competition exerted by dp14 and 12 (7 and
5% respectively) was not significant (P40.05). As the length of the
oligosaccharides decreased so did the level of competition seen.
Unexpectedly, the oligosaccharides dp10 and 8 caused a small
increase in binding of CXCL12 to solid-phase heparin.
When analysed over a range of concentrations both the dp14
and 12 oligosaccharides significantly competed with solid-phase
heparin at similar low concentrations (12.5mgml
 1; Po0.001),
whereas the dp10 and 8 oligosaccharides were required at much
higher concentrations (50mgml
 1 and in excess of 100mgml
 1
respectively) to achieve similar levels of competition (40%
inhibition; Figure 1B). The ability of the dp14, 12 and 10
oligosaccharides to compete CXCL12 from a more biologically
relevant solid phase of heparan sulphate was also measured.
As with the previous experiment both the dp14 and 12
oligosaccharides significantly competed for CXCL12 at similar
low concentrations (1mgml
 1), but higher concentration of the
dp10 oligosaccharides were required to exert the same level of
competition (Figure 1C).
Assessment of the effects of dp12 on breast cancer cell
migration in vitro
Following definition of dp12 as the shortest oligosaccharide to
significantly bind CXCL12, this size pool was assayed for its effect
on breast cancer cells in vitro. It was found that the migration of
breast cancer cells across transmembrane filters towards 12.5nM
CXCL12 was significantly inhibited in the presence of 25mgml
 1
(7mM) of the dp12 oligosaccharide (Po0.001; Figure 2). In the
presence of 100mgml
 1 of dp12 the number of migrant cells was
similar to the background level with no chemokine (P40.05).
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sAnalysis of the anticoagulant potential of heparinoids
An important aim of this study was to identify heparin
oligosaccharides that possess less anticoagulant activity than the
polymeric heparin molecule from which they are derived. To
achieve this anti-Xa levels were assessed in plasma isolated from
whole blood that had received doses of heparin (2.2mgml
 1),
Tinzaparin, a LMWH with a similar average molecular weight to
dp12 (3.4mgml
 1) and dp12 (3.4mgml
 1;1 mM) (Figure 3A). The
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Figure 1 The shortest length oligosaccharide of heparin capable of
significantly competing
125I-CXCL12 from solid-phase heparin or heparan
sulphate (50mgml
 1) was determined using radioligand competition
binding assays. (A) Initially a range of soluble oligosaccharides between
26 and 8 monosaccharide units in length and heparin (7mgml
 1), were
assessed with solid-phase heparin (50mgml
 1). The oligosaccharides dp14
(filled), dp12 (open), dp10 (hashed) and dp8 (dots) were then (B) used at
a range of concentrations to compete CXCL12 from heparin. Finally (C),
the dp14, dp12 and dp10 oligosaccharides were competed against a
heparan sulphate solid-phase for CXCL12 binding at a range of
concentrations (*Po0.001). Data are representative of three individual
experiments; bars show mean values7s.e.m.
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Figure 2 The effects of dp12 on the migration of breast cancer cells. The
number of LMD MDA-MB 231 cells migrating through 8mM pores towards
12.5nM CXCL12 was measured in the presence of varying concentrations
of the dp12 inhibitor (*Po0.001). The results are expressed as a
chemotactic index normalised to the number of migrating cells in the
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Figure 3 The anticoagulation properties of dp12. (A) Anti-Xa levels in
plasma isolated from whole blood receiving doses of heparin, tinzaparin
and an equivalent dose (weight) of dp12; therapeutic levels are between
0.5–1.0 anti-Xa IUml
 1.( B) Anti-Xa levels in whole blood containing
varying doses of dp12.
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sdoses of both heparin and Tinzaparin were given to achieve plasma
concentrations (0.2–0.4IUml
 1) that correspond to what is
clinically known as a therapeutic dose, with therapeutic anti-Xa
levels known to be in the range 0.5–1.0 anti-Xa IUml
 1. As there
was no known therapeutic dose of dp12 the same concentration
(weight) as that used for Tinzaparin was used. Both heparin and
Tinzaparin-treated blood showed anti-Xa IUml
 1 values within
the therapeutic range (0.64 and 0.71 anti-Xa IUml
 1) respectively.
However, the anti-Xa value for dp12-treated blood was
0.29IUml
 1, which is below therapeutic values. As the concentra-
tion of dp12 increased so did the anti-Xa IUml
 1 values, indicating
that dp12 is an effective anticoagulant at high concentrations
(Figure 3B).
Determination of the effects of heparin and dp12 on breast
cancer metastasis in vivo
LMD MDA-MB 231 cells (2 10
5) were administered intravenously
to three groups of seven SCID mice on day 1. The mice were
independently treated from days 0 to 28 with either subcutaneous
doses of heparin (3.3mg or 0.17mmolkg
 1day
 1;
600IUkg
 1day
 1) given twice daily, 0.1ml PBS given once daily,
or dp12 (4.0mg or 1.2mmolkg
 1day
 1) also given once daily. This
dose of heparin is known to produce therapeutic anticoagulation
in a clinical setting. Treatment of SCID mice with a single daily
dose of Tinzaparin at 175IUkg
 1day
 1 (1.8mg or
0.6mmolkg
 1day
 1) produces a level of anticoagulation, which
is just within the therapeutic range (0.51 anti-Xa IUml
 1); data not
shown. Given that Tinzaparin has an anticoagulant activity, which
is approximately 2.5 times greater than that of dp12, a sub-
anticoagulant dose of dp12 was chosen to dissociate anticoagulant
activity from any putative anticancer effect. The half-life of
LMWHs is two to four times that of unfractionated heparin; for
this reason, typical clinical regimes involve administration of
LMWHs once a day and heparin twice a day (Hirsh and Levine,
1992; Wu, 2001). As both dp12 and LMWHs are the result of
polymeric heparin degradation, dp12 was also administered once
a day.
A total of 20 sections from each mouse lung were assessed for
both the presence and the area of each metastatic lesion (Figure 4).
Dp12 had no effect upon the number of breast cancer metastases
found in the lungs when compared to control PBS-treated mice
(Figure 5A). However, the metastases within the lungs of dp12
treated mice were on average 41% smaller (Po0.05) than those
found in the PBS control mice (Figure 5B). Heparin decreased the
number of metastases by 87% (Po0.0001) compared to the PBS-
treated group (Figure 5A). No significant difference was identified
between the area of metastases in the heparin and the PBS-treated
groups (Figure 5B). Only three metastases were identified in the
heparin-treated animals (n¼7), therefore giving a large s.e.m. for
the average size of the lesions identified.
Assessment of the expression of CXCL12 on the lung
vascular endothelium and of CXCR4 on the formed
metastases
Both the expression of CXCR4 on cancer cells and CXCL12 on the
apical surface of vascular endothelium were examined to assess the
role played by chemokines in the anticancer activity of hepar-
inoids. The surface of normal lung endothelium expressed a high
level of CXCL12, which was not altered in PBS-treated control
animals (Figure 6A). Treatment with dp12 slightly decreased
CXCL12 expression while none of this chemokine was detected
on lung endothelium from heparin-treated mice (Figure 6A).
Tumours in both the heparin and dp12-treated mice showed a
small, but non-significant (P40.05), decrease in the expression of
CXCR4 mRNA in comparison with PBS-treated animals
(Figure 6B).
DISCUSSION
The metastasis of breast cancer cells to specific sites in the body is
the main cause of death for patients with this disease (Walker et al,
1997). Recent evidence has shown that this metastasis is mediated
through specific cell migration stimulated by the interactions of
C
A B
100 m 100 m
100 m
Figure 4 Representative haemotoxylin and eosin staining of tumours (arrows) in animals treated with (A) PBS, (B) heparin and (C) dp12 for 28 days
after intravenous administration of LMD MDA-MB 231 cells.
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sCXCL12, presented by heparan sulphate on the vascular endothe-
lium of organs commonly associated with breast cancer metastasis,
with CXCR4, expressed at high levels on metastatic breast cancer
cells (Muller et al, 2001). Previous studies have shown that heparin
is capable of antagonising chemokine function both in vitro and
in vivo (Castelli et al, 2004) indicating its potential to disrupt the
interaction between CXCL12 and CXCR4, thereby preventing the
invasion of CXCR4 expressing breast cancer cells (Dowsland et al,
2003). Clearly, the anticoagulant properties of heparin might limit
the usefulness of this molecule in treating breast cancer patients,
especially peri-operatively. This study has identified a short-chain
length oligosaccharide derived from polymeric heparin capable of
inhibiting the migration of breast cancer cells in vitro and limiting
the growth of secondary tumours in vivo, while minimising
potential anticoagulation problems associated with heparin.
The potential of defined-length heparin oligosaccharides to
compete with solid-phase heparin to bind CXCL12 was found to
decrease as the chain length decreased. Soluble heparin and the
oligosaccharides ranging from dp26 down to 16 in length all
competed significantly with solid-phase heparin, while oligo-
saccharides below 16 monomeric sugar units in length failed to
compete. In all cases, a similar amount (7mgml
 1) of defined-
length GAG was used to compete with heparin for chemokine
binding, suggesting that oligosaccharides containing 14 or fewer
monosaccharide units have a reduced potential to bind CXCL12.
However, heparinoids below dp14 did show some potential to bind
CXCL12 when present at greatly increased concentrations. The
most likely explanation for this observation is a reduction in the
number of the chemokine binding domains as the chain length of
the heparinoid molecule is reduced.
CXCL12 exists as a monomer in solution but forms dimers when
interacting with heparin or heparan sulphate (Veldkamp et al,
2005). The stoichiometry of the binding of CXCL12 to GAGs
suggests that each chemokine occupies an average of six
monosaccharide units on heparin (Altundag et al, 2005). However,
Sadir et al (2001) have shown that 13 monosaccharide units are
required for interaction with the dimeric form of CXCL12. This is
consistent with data in the current study and potentially explains
the greater degree of competition seen with dp14 and 12 than with
dp10 and 8 as the longer species are capable of binding dimeric
CXCL12, whereas the shorter can only bind monomeric CXCL12.
For these reasons, dp12 was chosen for further study.
Cell surface GAGs play important roles in the presentation of
chemokines to their specific receptors; these include protection
of chemokine molecules from degradation and the maintenance of
the stable concentration gradients through the tissues which are
required for vectorial cell migration (Perrimon and Bernfield,
2000). However, soluble GAGs have also been demonstrated to
antagonise the biological activity of chemokines (Douglas et al,
1997) potentially by production of chemokine-GAG complexes
which cannot engage specific chemokine receptors (Ali et al, 2000).
The current study confirmed these observations by demonstration
that dp12 inhibits the migration of breast cancer cells towards
CXCL12 in vitro.
The dp12 oligosaccharide had significantly less anticoagulant
activity than either heparin or Tinzaparin. As a consequence,
higher doses of dp12 were required to produce a similar level of
anti-Xa activity in blood. This can be explained in terms of the
relative length of the molecules. It is known that specific
pentasaccharide sequences are required for AT binding; these
motifs are present in about a third of heparin molecules (Lindahl
et al, 1979). However, only between 15 and 25% of the shorter
fragments present in LMWH contain this sequence (Lindahl et al,
1979; Lane et al, 1984; Hirsh, 1998; Herault et al, 2002). The
variation in the occurrence of the pentasaccharide between
LMWHs results in differences in their ability to bind AT and
therefore in inhibiting factor Xa (Nader et al, 2001). The cleavage
of heparin required to produce oligosaccharides is likely to disrupt
many of these sequence motifs, reducing the number available for
AT binding within a given weight of the processed material.
Importantly, however, the oligosaccharides retained their potential
to antagonise chemokine activity; this is consistent with previous
data from our group of the separation of anticoagulant and
chemokine-binding functions.
An in vivo breast cancer model was used to determine the ability
of heparin to prevent the metastasis of human breast cancer cells
from peripheral blood to the lung tissue of SCID mice;
importantly, heparin powerfully reduced the number of metastatic
lesions observed in the lung while treatment with the dp12
oligosaccharides had no effect on the number of lesions. Further
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Figure 5 Murine breast cancer model. Following administration of LMD
MDA-MB 231 cells, three groups of seven mice were treated for 28 days
with subcutaneous doses either of heparin (3.3mgkg
 1 per day) given
twice daily, 0.1ml PBS given once daily, or dp12 (4.0mgkg
 1 per day) also
given once daily. A total of 20 sections from each mouse lung were H&E
stained and assessed blindly using Leica Q win software for both the
number (A) of metastases and the area (B) of each metastasis identified
(*Po0.001); bars show mean values7s.e.m.
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chemokine antagonism in this model. Specifically, it was found
that treatment with heparin significantly reduced the expression
of CXCL12 on the endothelial and epithelial surfaces in the lung,
while dp12 only produced a small decrease in CXCL12 expression.
This suggests that heparin therapy reduces the potential of
CXCL12 to ‘capture’ cancer cells within breast tissues. However,
no reduction in the ratio between mRNA sequences encoding
human CXCR4 and GAPDH was observed in any treatment group
suggesting that the absence of immobilised CXCL12 in heparin-
treated animals did not select for non-CXCR4-expressing variants
of the cancer.
The tumours in the dp12-treated group were significantly
smaller in size than those in the PBS-treated control group.
Tumour growth is dependent not only on growth factors produced
by the cancer cells themselves but also those present in the
surrounding microenvironment. Heparinoids are very anionic
molecules that can bind and modulate the function of a wide range
of cytokines and adhesion molecules (Dowsland et al, 2003),
inducing numerous changes in the tissue microenvironment with
the potential to affect cancer cell growth. It is therefore most
probable that dp12 is affecting factors other than CXCL12 in
mediating its effects on tumour growth. For example, heparin
derivatives as short as eight monosaccharide units can bind both
FGF-2 and VEGF in vivo (Ishihara et al, 1993; Tyrrell et al, 1993;
Hurwitz et al, 2004); this prevents these growth factors from
binding to heparan sulphate leading to inhibition of angiogenesis
(Hasan et al, 2005). As these oligosaccharides prevent FGF-2 and
VEGF from binding to heparan sulphate, they function as
antagonists of angiogenesis and have been shown in vivo to
inhibit the development of new vasculature (Hasan et al, 2005).
However, it is important to stress that the action of heparin in
inhibiting breast cancer metastasis is potentially multifactorial,
and not solely the result of the inhibition of CXCL12/heparan
sulphate interactions. Studies examining the role of soluble
heparin in breast cancer have demonstrated a number of
mechanisms vital for breast cancer metastasis that can be
disrupted by heparin. These include the inhibition of the adhesion
and migration of breast cancer cells by heparin-mediated
inhibition of selectin binding and proteases These processes are
influenced to a greater degree by heparin than LMWHs and may
potentially explain the differences seen between heparin and dp12
(Vlodavsky et al, 1994; Koenig et al, 1998; Borsig, 2004). In
addition, if dp12 does function by inhibiting the action of growth
factors on the breast cancer cells it is unlikely that heparin will be
functioning in a similar manner with studies demonstrating a
promotional role for heparin in the presentation of growth factor
receptors, in contrast to shorter length oligosaccharides (Soker
et al, 1994; Norrby and Ostergaard, 1996).
In conclusion, these data show that relatively non-anticoagulant
concentrations of a soluble dp12 oligosaccharide can significantly
inhibit the migration of breast cancer cells in vitro, but only inhibit
the growth and not the number of lung metastases which form
in vivo. However, anticoagulant concentrations of heparin can
significantly inhibit both in vitro migration and the metastatic
spread of breast cancer cells in vivo. As viable cancer cells are
liberated into the vasculature during surgical resection, heparin
may offer a potential antimetastatic therapy. Although clinically
dp12 would not be applicable as an antimetastatic therapy it may
prove useful in inhibiting the growth of established tumours,
offering a potential treatment following diagnosis and before
surgery. The oligosaccharide may also prove beneficial to patients
with non-operable tumours by extending survival times.
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Figure 6 CXCL12 and CXCR4 expression in mouse lung and tumours. CXCL12 expression on the surface of the vascular endothelium was assessed by
immunohistochemical staining using a CXCL12 mouse monoclonal antibody (A) in mouse lung treated with PBS, heparin and dp12 for 28 days following
administration of LMD MDA-MB 231 cells (arrows); negative section is isotype control. There was strong CXCL12 staining on the vascular endothelium in
the PBS-treated group, which was unaltered in the dp12 group, whereas CXCL12 was absent from the vascular endothelium of the heparin-treated mice.
The levels of human CXCR4 expression (B), relative to PBS group, in tumours present in the mouse lung treated with heparin and dp12 for 28 days
following administration of LMD MDA-MB 231 cells were assessed using real-time PCR normalised to human GAPDH. Data are representative of three
individual experiments; bars show mean values7s.e.m.
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